Relapsed and Refractory Hodgkin Lymphoma

The management of relapsed and refractory (rel/ref) Hodgkin lymphoma (HL) has changed dramatically with the availability of brentuximab vedotin (BV) and checkpoint inhibitors. The data leading to approval of these agents and their incorporation into the treatment paradigm of rel/ref HL will be discussed.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Alison Moskowitz Source Type: research